FTC goes back to Teva on Cephalon deal

The Federal Trade Commission has requested additional information on Israel-based Teva Pharmaceutical Industries' planned acquisition of U.S. drugmaker Cephalon, potentially delaying regulatory clearance for another 30 days. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.